Clinical Trial Results:
Randomised, double-blind, cross-over Phase III study to investigate the efficacy and safety of hydromorphone after once daily administration of Hydromorphone HCl PR tablets XL in comparison to twice daily administration of Palladon® retard capsules in patients with chronic severe cancer or non-cancer pain.
Summary
|
|
EudraCT number |
2011-004471-37 |
Trial protocol |
DE SI PL |
Global completion date |
31 Aug 2012
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
06 Aug 2016
|
First version publication date |
06 Aug 2016
|
Other versions |
|
Summary report(s) |
1824/DEV |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.